AIGEN Sciences and Mepsgen Sign Memorandum of Understanding for Cooperation to Efficiently Develop Innovative New Drugs

On February 7, 2025 AIGEN Sciences reported that it has signed a memorandum of understanding (MOU) with Mepsgen (CEO Kim Yong-tae) to collaborate on the goal of efficient, innovative new drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, the two companies will explore ways to reduce bottlenecks in the new drug development process and implement more precise data analysis and efficient in vitro experimental models by combining Eigenscience’s AI-based new drug development platform and Mepsgen’s microphysiological system (MPS) technology.

Specifically, the company plans to verify new drug candidates designed and developed using Eigenscience’s AI platform using Mepsgen’s bio-tissue chips, and to continuously update the AI ​​platform by analyzing the efficacy and toxicity of the initial candidates.

Furthermore, by combining existing toxicity data held by Eisenscience with bio-tissue chip experiment data, we plan to establish a new research paradigm that predicts side effects in advance and verifies the safety of new drugs without animal testing by repeating this process.

This is expected to predict the likelihood of clinical trial success and dramatically shorten the existing new drug development period. The two organizations plan to continue strengthening their collaboration by building and expanding their global network.

"This agreement provides an opportunity to take MepsGen’s MPS technology to the next level and will serve as an important example of how AI technology can bring innovation to the new drug development process," said Jae-Woo Kang, CEO of Aizen Science.

"We expect to be able to accumulate highly reliable MPS data through our collaboration with Eisenscience, which will enable us to support more efficient and rapid new drug development," said Kim Yong-tae, CEO of Mepsgen.

(Press release, AIGEN Sciences, FEB 7, 2025, View Source;wr_id=53 [SID1234661232])